Mark Scharf, MD

Article

Vedolizumab-Induced Acne Fulminans: An Uncommon and Severe Adverse Effect

Author:: Mark Scharf, MD

Publish date: October 6, 2022

Vedolizumab, a monoclonal antibody for the treatment of refractory inflammatory bowel disease, was found to cause acne fulminans without systemic s...